Standard BioTools Inc. Common Stock (LAB)

FairStock Score: 56/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn consistent profits, generate cash, and sell at a sensible price. Standard BioTools does not yet fit. In fiscal 2025, the year ended 2025-12-31, revenue was $85.3M and net income was -$74.9M, or -$0.20 per diluted share. That follows fiscal 2024, the year ended 2024-12-31, with revenue of $91.0M and net loss of $138.9M, and fiscal 2023, the year ended 2023-12-31, with revenue of $106.3M and net loss of $74.7M. Revenue is moving the wrong way, and the company has lost money in each of the last four years, so FairStock assigns no Peter Lynch category. The latest filed quarter, fiscal Q2 2026, the quarter ended 2026-06-30, showed revenue of $20.1M and a net loss of $26.8M, or -$0.07 per diluted share; trailing free cash flow was -$82.6M, a -31.9% FCF yield on a $259.1M market cap. There was a striking net income in fiscal Q1 2026, the quarter ended 2026-03-31, of $127.1M, but the surrounding quarters remain loss-making, so I would not treat that as durable. The balance sheet has low debt (D/E 0.05), which helps, but FairStock's Altman Z-Score of 0.06 and Piotroski 2/9 signal financial fragility. At the $0.66 close on 2026-10-13, FairStock calculates P/B of 0.48 and P/E of -5.08; the price is low against book value, but returns are negative (ROE -11.18%, ROCE -6.61%). Without a path to consistent profit and cash generation, this is speculation, not a Graham margin of safety.

In plain English: Standard BioTools sells lab tools and services to scientists who study genes and proteins. The business looks weak right now: sales have been shrinking, it loses money, and it burns cash. The stock price is low compared with its accounting value, but because there are no profits, it is hard to call it a bargain; it looks like a speculative turnaround.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer